Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Public ClinicalTrials.gov record NCT05822752. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC
Study identification
- NCT ID
- NCT05822752
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Interventions
- Budigalimab Drug
- Lenvatinib Drug
- Livmoniplimab Drug
- Sorafenib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 20, 2023
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2026
- Last update posted
- Aug 13, 2025
2023 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313 | Prescott Valley | Arizona | 86314 | — |
| Highlands Oncology Group, PA /ID# 253158 | Springdale | Arkansas | 72762 | — |
| University of California, Los Angeles /ID# 253292 | Los Angeles | California | 90095 | — |
| UC Irvine /ID# 252707 | Orange | California | 92868 | — |
| California Pacific Medical Center - San Francisco - Webster Street /ID# 253291 | San Francisco | California | 94115 | — |
| Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163 | Denver | Colorado | 80218 | — |
| AdventHealth Orlando /ID# 252865 | Orlando | Florida | 32803 | — |
| The University of Chicago Medical Center /ID# 252870 | Chicago | Illinois | 60637-1443 | — |
| Hematology/Oncology Clinic /ID# 253851 | Baton Rouge | Louisiana | 70809 | — |
| Dana-Farber Cancer Institute /ID# 252696 | Boston | Massachusetts | 02215 | — |
| Henry Ford Hospital /ID# 253342 | Detroit | Michigan | 48202 | — |
| Washington University-School of Medicine /ID# 252698 | St Louis | Missouri | 63110 | — |
| NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 252708 | New York | New York | 10016-4744 | — |
| Memorial Sloan Kettering Cancer Center-Koch Center /ID# 252705 | New York | New York | 10065-6007 | — |
| Messino Cancer Center - Asheville /ID# 253888 | Asheville | North Carolina | 28806-2316 | — |
| University of North Carolina /ID# 252739 | Chapel Hill | North Carolina | 27514 | — |
| Lifespan Cancer Institute at Rhode Island Hospital /ID# 252699 | Providence | Rhode Island | 02903-4923 | — |
| Duplicate_Texas Oncology - Medical City Dallas /ID# 254164 | Dallas | Texas | 75230 | — |
| Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 252770 | Dallas | Texas | 75246-2003 | — |
| Texas Oncology - Northeast Texas /ID# 254184 | Tyler | Texas | 75702 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05822752, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05822752 live on ClinicalTrials.gov.